阿托伐他汀在体内外恢复免疫性血小板减少症中分化簇4(CD4)+ T细胞失衡
研究从免疫性血小板减少症(ITP)患者分离CD4+ T细胞,体外用不同剂量阿托伐他汀(AT)培养,发现AT抑制增殖、致细胞周期阻滞、诱导凋亡并抑制CD4+ T细胞活化。建立ITP小鼠模型后,AT治疗使血小板计数更快恢复至正常并表现出 comparable 免疫调节功能。体外AT处理后mTOR、AKT、ERK磷酸化及RAS活化均显著降低。
要点
- 阿托伐他汀体外抑制ITP患者CD4+ T细胞增殖、诱导凋亡并抑制活化。
- ITP小鼠模型中阿托伐他汀治疗使血小板计数更快恢复至正常。
- 阿托伐他汀经RAS/MEK/ERK和mTOR/PI3K/AKT通路恢复CD4+ T细胞功能。
核心结论
- 阿托伐他汀通过抑制CD4+ T细胞过度活化、增殖和存活,经RAS/MEK/ERK和mTOR/PI3K/AKT通路恢复ITP中CD4+ T细胞功能。
- 作者提出阿托伐他汀可作为ITP的潜在治疗选择,通过恢复过度活化的细胞免疫发挥作用。
研究设计与样本
- 体外研究:从ITP患者分离CD4+ T细胞,与不同剂量阿托伐他汀共培养。
- 体内研究:建立ITP小鼠模型,给予阿托伐他汀治疗。
主要发现
- 体外阿托伐他汀显著抑制CD4+ T细胞增殖、导致细胞周期阻滞、诱导凋亡并抑制CD4+ T细胞活化。
- ITP小鼠模型中阿托伐他汀治疗使血小板计数更快恢复至正常,并表现出 comparable 免疫调节功能。
- 体外阿托伐他汀处理后mTOR、AKT和ERK磷酸化及RAS活化均显著降低。
临床怎么用
- 作者提出阿托伐他汀可作为ITP的潜在治疗选择,通过恢复过度活化的细胞免疫发挥作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune thrombocytopenia (ITP) is an autoimmune haemorrhagic disease, in which the overactivation of T cells is crucial in the pathogenesis. Atorvastatin (AT), a lipid-lowering medicine, has shown promising immunomodulatory effects in certain inflammatory conditions. However, the immunoregulatory role of AT in ITP remains elusive. To investigate the effect of AT in the treatment of ITP, cluster of differentiation 4 (CD4)+ T cells were isolated from patients with ITP and cultured with different dosages of AT. We found that AT significantly inhibited cell proliferation, led to cell cycle arrest, induced apoptosis, and repressed the activation of CD4+ T cells in vitro. ITP murine models were then established, and results showed that AT treatment led to faster recovery of the platelet count to normal and exhibited comparable immunomodulatory function. Furthermore, we found the phosphorylation of mammalian target of rapamycin (mTOR), protein kinase B (AKT) and extracellular signal-regulated kinase (ERK), as well as activation of rat sarcoma virus (RAS) were all reduced dramatically after AT treatment in vitro. In conclusion, our present study demonstrated that AT could reinstate the functions of CD4+ T cells by inhibiting the excessive activation, proliferation, and survival of CD4+ T cells in ITP via the RAS/mitogen-activated protein kinase kinase (MEK)/ERK and the mTOR/phosphatidylinositol-3 kinase (PI3K)/AKT pathway. Therefore, we propose that AT could be used as a potential therapeutic option for ITP by restoring the over-activated cellular immunity.
引用
- Xu P, Zhao Y, Yu T, et al. Atorvastatin restores imbalance of cluster of differentiation 4 (CD4)+ T cells in immune thrombocytopenia in vivo and in vitro. Br J Haematol. 2021. PMID: 34825359. doi:10.1111/bjh.17938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。